Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Dr. Palmer on Molecular Abnormalities in Myeloproliferative Diseases

April 16, 2018

Jeanne M. Palmer, MD, hematologist oncologist, Mayo Clinic, discusses molecular abnormalities in myeloproliferative diseases, including polycythemia vera (PV) and the use of next-generation sequencing in identifying these mutations.

Dr. Stewart on the Role of Transplant in Multiple Myeloma

April 13, 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer

March 02, 2018

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Dr. Ho on How Molecular Subtypes Affect Sequencing

March 02, 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer

February 28, 2018

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings

January 25, 2018

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.